NDC 31722-005-32 - Mesalamine
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 31722-005
- Requested NDC
- 31722-005-32
- Package NDCs from labels
- 31722-005-32, 31722-005-30, 31722-005-31
- Manufacturer
- Camber Pharmaceuticals, Inc. | Annora Pharma Private Limited
- Effective date
- 2024-02-26
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Mesalamine - Camber Pharmaceuticals, Inc. | Annora Pharma Private Limited | Camber Pharmaceuticals, Inc. | Annora Pharma Private Limited | 2024-02-26 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 31722-005-30 | Mesalamine | 5 in 1 CARTON | SUPPOSITORY | 5 | 4 | |
| 31722-005-31 | Mesalamine | 7 in 1 CARTON | SUPPOSITORY | 7 | 4 | |
| 31722-005-32 | Mesalamine | 6 in 1 PACKAGE | SUPPOSITORY | 6 | 4 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 31722-005-30 | EA - Each | 31722-005 | 280c6a2e-f10e-44c7-acb8-89fcda18781e | 1 | 2020-09-14 |
| 31722-005-32 | EA - Each | 31722-005 | d00e030e-2fbc-477d-9788-c29745075145 | 1 | 2020-09-14 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| APRISO | MESALAMINE | Salix Pharmaceuticals, Inc. | 7951139c-b271-45a4-b523-34b23800917b | 2026-08-27 | Warnings, Adverse reactions | 4Q81I59GXC |
| Rowasa | MESALAMINE | Viatris Specialty LLC | e505ab99-1943-4216-a178-4d5dbe64e3b2 | 2026-08-03 | Warnings, Adverse reactions | 4Q81I59GXC |
| mesalamine | MESALAMINE | Major Pharmaceuticals | 14ac4435-903b-41f5-a3c4-8c73de3e4cef | 2026-07-27 | Warnings, Adverse reactions | 4Q81I59GXC |
| mesalamine | MESALAMINE | Zydus Pharmaceuticals USA Inc. | ad8c7930-92e2-4372-a874-da22b9ae333e | 2026-07-14 | Warnings, Adverse reactions | 4Q81I59GXC |
| Mesalamine | MESALAMINE | Sandoz Inc | 47b5d1ee-b439-4ccb-9b01-c0875ccd748a | 2026-06-30 | Warnings, Adverse reactions | 4Q81I59GXC |
| Mesalamine | MESALAMINE | Nuvaila Limited | 875d573f-99a1-426a-8321-4d511690d503 | 2026-06-03 | Warnings, Adverse reactions | 4Q81I59GXC |
| Mesalamine | MESALAMINE | ANI Pharmaceuticals, Inc. | 485ed763-976e-4410-a401-7ff762a931b3 | 2026-05-20 | Warnings, Adverse reactions | 4Q81I59GXC |
| MESALAMINE | MESALAMINE | KLM Laboratories Private Limited | 54cfed92-5e28-4a4d-a70f-2a60b5b54c12 | 2026-04-01 | Warnings, Adverse reactions | 4Q81I59GXC |
| Lialda | MESALAMINE | Takeda Pharmaceuticals America, Inc. | 3098a080-be86-4265-9818-7fc4beab77b7 | 2026-03-24 | Warnings, Adverse reactions | 4Q81I59GXC |
| Mesalamine | MESALAMINE | Golden State Medical Supply, Inc. | 4c4ffb68-3ca4-35cd-e063-6294a90ab929 | 2026-03-05 | Warnings, Adverse reactions | 4Q81I59GXC |
| Mesalamine | MESALAMINE | Actavis Pharma, Inc. | 73317da3-cba0-4106-9e88-79b0e2f642af | 2026-02-24 | Warnings, Adverse reactions | 248420 4Q81I59GXC |
| Mesalamine | MESALAMINE | AvKARE | 22f3ee49-ac57-84f5-e063-6394a90aae91 | 2026-01-14 | Warnings, Adverse reactions | 4Q81I59GXC |
| Mesalamine | MESALAMINE | Chartwell RX, LLC | 9703f92d-1d15-4376-8b2b-51502c266012 | 2025-12-17 | Warnings, Adverse reactions | 4Q81I59GXC |
| MESALAMINE | MESALAMINE | Camber Pharmaceuticals, Inc. | ef471372-8d9f-4d95-9371-44522c69058f | 2025-12-10 | Warnings, Adverse reactions | 4Q81I59GXC |
| Mesalamine | MESALAMINE | Rising Pharma Holdings, Inc. | c26ae6cb-041b-4cfc-90ca-c4e1cb23458c | 2025-12-10 | Warnings, Adverse reactions | 248420 4Q81I59GXC |
| Mesalamine | MESALAMINE | Ingenus Pharmaceuticals, LLC | 58503afe-b8d4-4710-a194-e3acd64ecf1f | 2025-12-05 | Warnings, Adverse reactions | 4Q81I59GXC |
| Mesalamine | MESALAMINE | Upsher-Smith Laboratories, LLC | 1e6978d0-01db-477d-a90f-27561777480f | 2025-12-01 | Warnings, Adverse reactions | 4Q81I59GXC |
| Mesalamine | MESALAMINE | Encube Ethicals, Inc. | d6b68275-b2a4-4965-9862-cf14acf8c599 | 2025-10-07 | Warnings, Adverse reactions | 4Q81I59GXC |
| Mesalamine | MESALAMINE | Teva Pharmaceuticals USA, Inc. | 6fd0a906-e1b5-4238-a79b-a195510ddc84 | 2025-05-30 | Warnings, Adverse reactions | 4Q81I59GXC |
| Mesalamine | MESALAMINE | American Health Packaging | e638681d-8fca-4bf8-a1fb-8e52357a64da | 2025-05-21 | Warnings, Adverse reactions | 4Q81I59GXC |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.